Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

00420 224 910 672

(from 09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

00420 224 910 672

(09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

Fast-growing regulatory affairs service provider ELC Group expands corporate presence in Czech Republic

Major contract wins in China and US fuel latest move into larger premises in Prague

Cambridge, UK, 24th February, 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it is expanding its office presence in Prague in the Czech Republic due to accelerating company growth. From May, ELC Group will be occupying nearly 2000 square metres of offices at Danube House, located in the prime River City Prague business district.

The move is being fuelled by ELC Group’s rapidly expanding customer base, which includes recent major contract wins in China and the US. The increased office space will accommodate ELC Group’s growing team of project management staff and subject matter experts, with staff numbers based in the Czech capital set to almost double within the next three months.

ELC Group’s corporate strategy has delivered a sustained period of exceptional growth over the past five years, leading to the opening of new and expanded operational offices in Mumbai, Ahmedabad, Singapore and Russia, and the establishment of a new global headquarters in Cambridge, UK. ‘From Concept to Commercialisation’ is one of the new, key partnership areas in which ELC Group is creating its success, offering expert consultancy services from the development stage through to the implementation of clinical trials, completion of product registration, and successful product marketing. In a further extension of its solution portfolio, in 2012 ELC Group also announced the launch of a software subsidiary – Pharma eReport – which is now successfully delivering a complete and proven XEVMPD compliance solution for major global pharmaceutical Marketing Authorisation Holders.

Commenting on the Prague office expansion, ELC Group CEO Marco Rubinstein said: “ELC Group is fast becoming one of the industry’s stand-out success stories. Our unmatched sector experience, strong track record of delivery, and our world-class team of experts mean that our services are more in demand than ever, and we are very proud to be expanding our presence in the Czech Republic, which provided the base for ELC Group’s phenomenal development from the very beginning.”